WHAT IS CLAIMED IS:

1. The use of a pharmaceutical composition comprising:
   a. about 50 mg or less of a diclofenac compound; and
   b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain, wherein the post-operative pain results from orthopedic surgery.

2. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac compound.

3. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac compound.

4. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac compound.

5. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

6. The use of a pharmaceutical composition comprising:
   a. about 50 mg or less of a diclofenac compound; and
   b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain, wherein the post-operative pain results from abdominal or pelvic surgery.

7. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 6, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac compound.

8. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 6, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac compound.

9. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 6, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac compound.

10. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 6, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

11. The use of a pharmaceutical composition comprising:

a. about 37.5 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of pain, wherein the pain results from cancer.

12. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 11, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

13. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal, wherein the post-operative pain results from orthopedic surgery.

14. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having a high-risk of an adverse reaction to analgesia, wherein the post-operative pain results from orthopedic surgery.

15. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in a manufacture of a medicament for the treatment of post-operative pain in a mammal weighing at least about 210 lbs. (95 kg), wherein the post-operative pain results from orthopedic surgery.

16. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having hepatic impairment, wherein the post-operative pain results from orthopedic surgery.

17. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having renal impairment, wherein the post-operative pain results from orthopedic surgery.

18. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal of at least about 65 years old, wherein the post-operative pain results from orthopedic surgery.

19. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal suffering from moderate to severe pain, wherein the post-operative pain results from orthopedic surgery.

20. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac compound.

21. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac compound.

22. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac compound.

23. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

24. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal, wherein the post-operative pain results from abdominal or pelvic surgery.

25. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal weighing at least about 210 lbs. (95 kg), wherein the post-operative pain results from abdominal or pelvic surgery.

26. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having hepatic impairment, wherein the post-operative pain results from abdominal or pelvic surgery.

27. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having renal impairment, wherein the post-operative pain results from abdominal or pelvic surgery.

28. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal of at least about 65 years old, wherein the post-operative pain results from abdominal or pelvic surgery.

29. The use of a pharmaceutical composition comprising:

a. about 50 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal suffering from moderate to severe pain, wherein the post-operative pain results from abdominal or pelvic surgery.

30. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 24, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac compound.

31. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 24, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac compound.

32. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 24, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac compound.

33. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 24, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

34. The use of a pharmaceutical composition comprising:

a. about 37.5 mg or less of a diclofenac compound; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of pain in a mammal, wherein the pain results from cancer.

35. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 34, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

WHAT IS CLAIMED IS:

1. The use of a pharmaceutical composition comprising:

a. from 5mg to 37.5 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative moderate to severe pain, wherein the post-operative pain results from orthopedic surgery in a mammal having hepatic and/or renal impairment, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

2. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

3. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

4. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 1, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

5. The use of a pharmaceutical composition comprising:

a. from 5mg to 37.5 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative moderate to severe pain in a mammal of at least about 65 years old, wherein the post-operative pain results from orthopedic surgery, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

6. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 5, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

7. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 5, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

8. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 5, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

9. The use of a pharmaceutical composition comprising:

a. from 5mg to 37.5 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative moderate to severe pain, wherein the post-operative pain results from abdominal or pelvic surgery in a mammal having hepatic and/or renal impairment, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

10. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 9, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

11. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 9, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

12. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 9, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

13. The use of a pharmaceutical composition comprising:

a. from 5mg to 37.5 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative moderate to severe pain in a mammal of at least about 65 years old, wherein the post-operative pain results from abdominal or pelvic surgery, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

14. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

15. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

16. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 13, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

17. The use of a pharmaceutical composition comprising:

a. from 5mg to 50 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in a manufacture of a medicament for the treatment of post-operative moderate to severe pain in a mammal weighing at least about 210 lbs. (95 kg), wherein the post-operative pain results from orthopedic surgery, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

18. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 17, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

19. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 17, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

20. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 17, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

21. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 17, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

22. The use of a pharmaceutical composition comprising:

a. from 5mg to 50 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative moderate to severe pain in a mammal weighing at least about 210 lbs. (95 kg), wherein the post-operative pain

results from abdominal or pelvic surgery, wherein the mammal does not require dose reduction of the diclofenac or pharmaceutically acceptable salt thereof.

23. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 22, wherein the pharmaceutical composition comprises about 37.5 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

24. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 22, wherein the pharmaceutical composition comprises about 18.75 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

25. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 22, wherein the pharmaceutical composition comprises about 9.375 mg or less of diclofenac or a pharmaceutically acceptable diclofenac salt.

26. The use of the pharmaceutical composition in the manufacture of a medicament as claimed in claim 22, wherein the beta-cyclodextrin compound is hydroxypropyl-beta-cyclodextrin (HPβCD).

27. The use of a pharmaceutical composition comprising:

a. from 5mg to 50 mg of diclofenac or a pharmaceutically acceptable diclofenac salt; and

b. a beta-cyclodextrin compound;

in the manufacture of a medicament for the treatment of post-operative pain in a mammal having a high-risk of an adverse reaction to analgesia, wherein the post- operative pain results from orthopedic surgery.